Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?

ISSN： 0785-3890

Source： Annals of Medicine, Vol.44, Iss.4, 2012-06, pp. : 338-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

By Ross Stuart A. Ballantine Jane

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1617-1626

Informa Healthcare

Access to resources Recommend Favorite

GLP-1 receptor agonists and HBA_1c target of <7%% in type 2 diabetes: meta-analysis of randomized controlled trials

By Esposito K. Mosca C. Brancario C. Chiodini P. Ceriello A. Giugliano D.

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1519-1528

Informa Healthcare

Access to resources Recommend Favorite

Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 16, Iss. 7, 2014-07 ,pp. : 588-601

John Wiley & Sons Inc

Access to resources Recommend Favorite

Liraglutide: a human GLP-1 analog for Type 2 diabetes

By Vilsbøøll Tina

Therapy, Vol. 6, Iss. 2, 2009-03 ,pp. : 199-207

Future Medicine

Access to resources Recommend Favorite

Dulaglutide: a once‐weekly GLP‐1 for type 2 diabetes

PRESCRIBER, Vol. 26, Iss. 19, 2015-10 ,pp. : 28-30

John Wiley & Sons Inc

Access to resources Recommend Favorite